HCPCS Q4239 is officially defined as "Amnio-maxx or amnio-maxx lite, per square centimeter (add-on, list separately in addition to primary procedure)." HCPCS Q4239 is referenced in 8 tracked payer policy changes from Sentara Health Plans, HealthPartners, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q4239 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Starting January 1, 2027, Sentara Health Plans will require prior authorization for a long list of codes on Virginia commercial plans, including self-funded (ASO) plans, and for code 88380 on commercial, Medicaid and Medicare products, plus code 22860 on Medicare products. Sentara will also stop covering a separate list of codes on Virginia commercial and self-funded plans.
HealthPartners' January 2026 Fast Facts newsletter reports several provider-facing changes: pharmacy claims administration moving to Express Scripts effective January 1, 2026; commercial drug formulary replacements (Humira/Hadlima, Lantus, Ventolin HFA) with biosimilar or generic alternatives; new and revised medical coverage policies (including non-covered services added and aquablation for BPH criteria changed) Reported as already effective in the historical source as of 01/01/2026; and a reminder that providers must not bill QMB members for Medicare Part A/B cost sharing. Because the source is dated 2026-01-01 and the analysis date is 2026-11-06, these items are historical; billing staff should verify current applicability in the live formulary and coverage policies rather than treat them as pending deadlines.
Health Net California is updating prior authorization requirements effective December 1, 2025, removing PA requirements for many DME items, prosthetics, sleep studies, varicose vein treatments, and therapy services while maintaining PA requirements for non-emergency air transport, hysterectomies, and skin substitutes. These changes aim to reduce administrative burden and streamline approval processes.
Health Net updated 16 medical policies with new prior authorization requirements, billing code changes, and coverage criteria changes for Q2 2021. Key changes include new CPT codes for ADHD testing that are now not medically necessary, updated HCPCS codes for skin substitutes, and revised criteria for multiple procedures including gender affirming care and spinal cord stimulation.
Health Net updated multiple medical policies for Q2 2021, including new policies for TMS treatment, EMG/nerve studies, and nasal valve repair, plus significant updates to ADHD testing codes, gender affirming procedures, and pain management nerve blocks. Multiple CPT, HCPCS, and ICD-10 codes were added, removed, or modified across various specialties.
CalViva Health (Medi-Cal) updated multiple medical policies for Q2 2021, affecting prior authorization requirements, billing codes, and coverage criteria across numerous specialties. Key changes include updated CPT codes for ADHD testing, nerve studies, and spinal procedures, plus revised criteria for gender-affirming procedures, pain management, and wound care.
Michigan Medicaid has revised its policy for skin and tissue substitutes, effective June 5, 2026. Coverage is limited to specific diabetic foot ulcers and chronic venous leg ulcers over 4 weeks duration when used with comprehensive standard wound therapy, with strict documentation requirements for all criteria.
Effective January 1, 2026, HealthPartners transitioned its pharmacy benefits claims administration to Express Scripts, Inc. (ESI). Formulary opioid edits, including prior authorization requirements, quantity limits and cumulative dose restrictions, apply to all providers across all lines of business, and previously granted exceptions were discontinued on January 1. On the commercial drug formulary, Ventolin HFA has been removed and replaced with the generic, Humira and Hadlima are being removed with adalimumab-aaty, adalimumab-fkjp and adalimumab-adaz (10mg only) added as replacements, and Lantus is being removed and replaced with insulin-yfgn. Medical policy updates dated 01/01/2026 were Reported as already effective in the historical source and added confocal laser endomicroscopy (CPT 0397T), pressure-enabled drug delivery (TriNav Infusion System), certain skin and soft tissue substitutes, and transcatheter mitral valve replacement or implantation (CPT 0483T, 0484T) to the investigational services list as non-covered, and removed the medication trial requirement before aquablation for benign prostatic hyperplasia (BPH).
Watch Q4239
Get one email when a payer policy names Q4239, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for Q4239
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for Q4239 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.